KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of
an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.
Author: ModernMedecine
EDI-OCT aids in glaucoma imaging
Focal lamina cribrosa defects were highly correlated with glaucomatous structural and functional
damage in an evaluation performed with EDI-OCT.
Upper age limit for retinopathy of prematurity screening could be lowered
Full Story →
Device delivers glaucoma medication
In a pilot phase II study, an intracanalicular plug (OTX-TP2, Ocular Therapeutics) shows promise for
lowering IOP and increasing compliance with the treatment regimen.
Avedro, EyeGate Pharma to enter agreement
EyeGate Pharma’s broad iontophoresis patent portfolio for corneal collagen cross-linking
will be held as exclusive license by Avedro Inc. Delivery approach provides potential additional benefits to
current formulation.
Postop haze not affected by MMC
Mitomycin C following wavefront-guided PRK for high myopia had no dose-dependent effect on haze scores
throughout the study.
PBA declares November Diabetic Eye Disease Awareness Month
Prevent Blindness America offers free educational materials to help the public, educators, and health
professionals address diabetes and its visual consequences.
Aflibercept and ranibizumab comparable in macular degeneration
NEW YORK (Reuters Health) – They’re similarly effective and safe for neovascular age-related macular
degeneration, but intravitreal aflibercept might have an edge over ranibizumab in convenience, researchers
say.
George Spaeth, MD, named recipient of Robert Ritch award
The Glaucoma Foundation has announced George L. Spaeth, MD, as the 2012 recipient of the
foundation’s Dr. Robert Ritch Award for Innovation and Excellence in
Glaucoma.
Dual-optic accommodating IOL often preferred
Current multifocal IOLs have some limitations that in specific situations are overcome with the
dual-optic accommodating IOL (Synchrony, Abbott Medical Optics).
Nicox presents diagnostic device for conjunctivitis in United States
Nicox S.A. announced the U.S. launch of a point-of-care diagnostic test (AdenoPlus) that aids in the
differential diagnosis of acute conjunctivitis.
SARcode reports phase III results for lifitegrast
SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of
lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.
Nicox presents diagnostic device for conjunctivitis in U.S.
Nicox S.A. announced the U.S. launch of AdenoPlus, a point-of-care diagnostic test that aids in the
differential diagnosis of acute conjunctivitis.
Instrument-based vision screening best in 3- to 5-year-olds
NEW YORK (Reuters Health) – A new policy statement from the American Academy of Pediatrics published
Monday recommends photoscreening and handheld autorefraction as an alternative to visual acuity screening with
vision charts in children aged t…
VMA treatment approved
The FDA has approved ocriplasmin (Jetrea, ThromboGenics) for the treatment of symptomatic
vitreomacular adhesion (VMA).
Intracameral treatment lowers post-op infection risk
Antibiotic injections following cataract surgery were found to reduce risk of post-op endophthalmitis
by 22-fold.
To lift or not to lift?
A new strategy that uses the femtosecond laser to make a side cut for post-LASIK re-treatment may
reduce the incidence of epithelial ingrowth.
FDA advises patient notification
The FDA advises health-care professionals to follow up with patients for whom they administered an
injectable product purchased from or produced by NECC.
Intracameral treatment lowers postop infection risk
Antibiotic injections following cataract surgery were found to reduce risk of postop endophthalmitis
by 22-fold.
Implanted lens or contact lens after unilateral congenital cataract surgery?
NEW YORK (Reuters Health) – In infants having surgery for a unilateral congenital cataract, the
short-term costs are lower with contact lenses instead of an implanted intraocular lens and glasses, a new study
shows.